This Research Topic is one volume within the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the series
here.
The inflammatory tumor microenvironment (TME) is a pivotal area of research in hematological malignancies, given its intricate interactions with the immune system. This field has garnered significant attention due to the TME's role in promoting cancer cell survival, growth, and resistance to therapy. Current challenges include understanding how cytokines, chemokines, immune checkpoints, and immune cells contribute to a pro-tumorigenic niche and the impact of chronic inflammation on disease progression. Recent studies have highlighted the multifaceted role of the TME in the development of leukemia, lymphoma, and multiple myeloma, emphasizing the need for a deeper understanding to improve treatment strategies. Despite advancements, gaps remain in fully elucidating the mechanisms by which the innate and adaptive immune systems sustain a pro-tumorigenic environment, underscoring the necessity for further investigation into novel therapeutic approaches.
This research topic aims to explore the current knowledge of the mechanisms by which the innate and adaptive immune systems support the development of a pro-tumorigenic niche in hematological malignancies. The objective is to advance understanding of tumor-TME dynamics and foster the development of novel anti-inflammatory and anti-immune therapeutic strategies. By addressing these mechanisms, the research seeks to improve patient outcomes by identifying effective therapeutic options for blood cancers.
To gather further insights into the complex interactions within the TME in hematological malignancies, we welcome Original Research, Clinical Trials, Systematic Reviews, Reviews/Mini-Reviews, and Perspectives articles addressing, but not limited to, the following themes:
- Role of the TME in leukemia, lymphoma, and multiple myeloma
- Studies on innate and adaptive immune responses relevant to immunotherapy
- Studies defining the role of cytokines, chemokines, immune checkpoints, receptor-ligand interactions, and adhesion molecules in the TME
- Use of cellular therapies and T-cell engagers in leukemia, lymphoma, and multiple myeloma
- Novel combinations with immune checkpoint inhibitors
- Novel combinations with monoclonal antibodies and bispecific antibodies
- Cytokine-based immunotherapy
- Vaccine-based immunotherapy
Topic Editor Andrea Visentin is on the advisory board organized by Johnson&Johnson, Abbvie, BeiGene, AstraZeneca, and Takeda. They have also received financial support from Johnson&Johnson, BeiGene, AstraZeneca, and Taleda. The other Topic Editors declare no competing interests with regard to the Research Topic subject.